# A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer

> **NCT04890795** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Advenchen Laboratories Nanjing Ltd.** · enrollment: 237 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** AL8326 tablets

## Key facts

- **NCT ID:** NCT04890795
- **Lead sponsor:** Advenchen Laboratories Nanjing Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-19
- **Primary completion:** 2021-09
- **Final completion:** 2021-09
- **Target enrollment:** 237 (ESTIMATED)
- **Last updated:** 2021-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04890795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04890795, "A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04890795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*